Overview
flowchart TD
entities_virma_kiaa1429["VIRMA KIAA1429"]
style entities_virma_kiaa1429 fill:#4fc3f7,stroke:#333,color:#000
entities_virma_kiaa1_0["Structure and Function"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_0
style entities_virma_kiaa1_0 fill:#81c784,stroke:#333,color:#000
entities_virma_kiaa1_1["Protein Architecture"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_1
style entities_virma_kiaa1_1 fill:#ef5350,stroke:#333,color:#000
entities_virma_kiaa1_2["Role in the m6A Methyltransferase Complex"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_2
style entities_virma_kiaa1_2 fill:#ffd54f,stroke:#333,color:#000
entities_virma_kiaa1_3["m6A Modification Biology"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_3
style entities_virma_kiaa1_3 fill:#ce93d8,stroke:#333,color:#000
entities_virma_kiaa1_4["The m6A Modification"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_4
style entities_virma_kiaa1_4 fill:#4fc3f7,stroke:#333,color:#000
entities_virma_kiaa1_5["Writing, Reading, and Erasing m6A"]
entities_virma_kiaa1429 -->|"includes"| entities_virma_kiaa1_5
style entities_virma_kiaa1_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
VIRMA (Virus-Induced RNA Methyltransferase Associated protein), also known as KIAA1429, is a key component of the N6-methyladenosine (m6A) methyltransferase complex that catalyzes the most prevalent internal modification of messenger RNA in eukaryotic cells["@liu2019"]. This large protein (approximately 1,500 amino acids) plays a critical role in regulating RNA metabolism through its involvement in m6A deposition, which affects RNA splicing, stability, translation, and subcellular localization["@yue2020"].
The protein is encoded by the KIAA1429 gene (also called VIRMA or Virmatin), located on chromosome 18q21.1 in humans. It is highly conserved across species and is expressed in various tissues, with particularly high expression in the brain, indicating important functions in neuronal cells.
Structure and Function
Protein Architecture
VIRMA is a modular protein containing several functional domains:
- N-terminal region: Contains multiple low-complexity regions that may mediate protein-protein interactions
- Central region: Harbors the signature motifs for RNA binding and methyltransferase activity
- C-terminal domain: Involved in complex formation with other m6A writer components
The protein lacks canonical methyltransferase activity itself but serves as a scaffold that coordinates the assembly and function of the m6A methyltransferase complex[@liu2019].
Role in the m6A Methyltransferase Complex
VIRMA is a core component of the "m6A writer" complex, which includes[@yue2020]:
- METTL3: The catalytically active methyltransferase subunit
- METTL14: A structural partner that recognizes target RNA sequences
- WTAP: The regulatory subunit that mediates nuclear localization
- VIRMA/KIAA1429: The largest scaffold protein that coordinates complex assembly
- ZC3H13: Additional regulatory component
VIRMA specifically mediates the interaction between the catalytic core (METTL3/METTL14) and the regulatory components (WTAP), ensuring proper complex formation and targeting to specific RNA substrates[@liu2019].
m6A Modification Biology
The m6A Modification
N6-methyladenosine (m6A) is the most abundant internal modification of messenger RNA in eukaryotes, occurring on average at 1-3 sites per mRNA molecule[@dominissini2012]. This modification is dynamic and reversible, regulated by "writers" (methyltransferases), "readers" (methylation-sensitive binding proteins), and "erasers" (demethylases)[@roundtree2017].
Key functions of m6A include:
- Alternative splicing regulation: m6A marks influence spliceosome recruitment and alternative splicing patterns
- mRNA stability control: m6A-modified transcripts are targeted for degradation or stabilization by reader proteins
- Translation regulation: m6A affects translation initiation and efficiency through reader protein-mediated mechanisms
- Nuclear export: m6A modification influences mRNA export from the nucleus
- Cellular localization: m6A can affect the subcellular distribution of specific transcripts
Writing, Reading, and Erasing m6A
The m6A machinery operates through a coordinated system[@yue2020]:
Writers (Methyltransferases):
- METTL3: Catalytic subunit with SAM-binding motifs
- METTL14: Substrate recognition and binding
- WTAP: Regulatory subunit for nuclear speckle localization
- VIRMA: Scaffold for complex assembly
Readers (M6A-binding proteins):
- YTH domain family proteins (YTHDF1-3, YTHDC1-2): Recognize and interpret m6A marks
- IGF2BP proteins: Stabilize target mRNAs
- HNRNPC: Affects alternative splicing via m6A binding
Erasers (Demethylases):
- FTO: First discovered m6A demethylase[@shi2012]
- ALKBH5: Nuclear demethylase affecting mRNA export
VIRMA in RNA Processing
Transcriptional Regulation
VIRMA's role in m6A modification directly impacts multiple aspects of RNA processing:
Pre-mRNA splicing: m6A marks influence splice site selection and alternative splicing. VIRMA deficiency leads to aberrant splicing patterns[@liu2019]
Polyadenylation: m6A affects alternative polyadenylation site selection
RNA stability: VIRMA-mediated m6A regulates transcript stability through reader protein interactions
Translation efficiency: m6A-modified transcripts show altered translation kineticsm6A Deposition Patterns
VIRMA shows preferential targeting of:
- 3' untranslated regions (UTRs) near stop codons
- Long internal exons
- Transcript start sites
- Specific sequence motifs (GGACU)[@dominissini2012]
The specificity of m6A deposition is determined by the combined action of METTL3/METTL14 substrate recognition and VIRMA-mediated complex positioning.
Connection to Neurodegeneration
m6A in Brain Function and Disease
Emerging research demonstrates critical roles for m6A modification in brain development, neuronal function, and neurodegenerative diseases[@zhao2021]:
Synaptic function: m6A regulates synaptic plasticity-related gene expression
Neurodevelopment: m6A affects neural progenitor cell differentiation
Aging: m6A patterns change during aging and in age-related diseasesm6A and Neurodegenerative Disease Mechanisms
While direct evidence linking VIRMA to specific neurodegenerative diseases is still emerging, the broader m6A pathway has been implicated in:
Alzheimer's disease: Altered m6A levels in AD brains correlate with disease progression. m6A modification affects [APP](/entities/app-protein) processing and [tau](/proteins/tau) phosphorylation pathways[@zhang2023]
Parkinson's disease: m6A regulators show altered expression in PD models. The pathway affects [alpha-synuclein](/proteins/alpha-synuclein) expression and mitochondrial function[@huang2024]
Amyotrophic lateral sclerosis (ALS): m6A dysregulation has been observed in ALS models
Neuroinflammation: m6A modification regulates cytokine expression and immune responses in the brainMultiple neurodegenerative diseases are characterized by RNA metabolism defects:
- [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathies (ALS, FTD): TDP-43 regulates RNA splicing; may interact with m6A pathways
- Spinocerebellar ataxias: RNA binding protein defects affect RNA processing
- Myotonic dystrophy: MBNL1 dysfunction affects alternative splicing
VIRMA-mediated m6A modifications may contribute to these RNA metabolism defects through:
- Altered splicing of disease-related genes
- Aberrant stability of transcripts encoding toxic proteins
- Dysregulated translation of neuroprotective factors
Photoreceptor Degeneration
Recent studies have shown that VIRMA modulates photoreceptor cell function through m6A modification, linking RNA methylation to retinal degeneration[@wang2024]. This suggests VIRMA may play a role in maintaining photoreceptor viability, with implications for understanding neurodegeneration in the retina and potentially the brain.
Therapeutic Implications
Targeting the m6A Pathway
The m6A pathway represents a potential therapeutic target for neurodegenerative diseases[@chen2024]:
Small molecule modulators: Development of METTL3/METTL14 inhibitors or activators
FTO inhibitors: Blocking demethylase activity to increase m6A levels
Reader protein targeting: Modulating m6A reader function to affect specific disease pathwaysChallenges and Opportunities
- Specificity: Achieving cell-type and pathway-specific targeting
- Delivery: Effectively delivering modulators to the brain
- Understanding: Need for more detailed understanding of m6A's role in specific neuronal functions
Research Directions
Future research should focus on:
- Identifying VIRMA-specific targets in [neurons](/entities/neurons)
- Understanding how VIRMA dysfunction contributes to specific disease mechanisms
- Developing VIRMA activity modulators
- Exploring VIRMA's role in non-coding RNA processing
Cross-References
- [m6A Methylation](/mechanisms/m6a-methylation)
- [METTL3](/entities/mettl3-protein)
- [RNA Processing](/mechanisms/rna-processing)
- [Epigenetics in Neurodegeneration](/mechanisms/epigenetics-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
- [Allen Human Brain Atlas](https://brain-map.org/)
References
[Liu J, et al, VIRMA mediates m6A deposition in RNA (2019)](https://pubmed.ncbi.nlm.nih.gov/30078761/)
[Yue Y, et al, m6A writer complex: structure and function (2020)](https://doi.org/10.1016/j.tcb.2020.04.001)
[Roundtree IA, et al, Dynamic m6A modification in RNA metabolism (2017)](https://pubmed.ncbi.nlm.nih.gov/28957406/)
[Zhao BS, et al, m6A-dependent pathway in synaptic plasticity and learning (2021)](https://pubmed.ncbi.nlm.nih.gov/34536354/)
[Zhang C, et al, m6A modification in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36913542/)
[Huang H, et al, m6A in Parkinson's disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38149892/)
[Dominissini D, et al, Topology of the human m6A epitranscriptome (2012)](https://pubmed.ncbi.nlm.nih.gov/23177736/)
[Shi H, et al, m6A erasure by FTO (2012)](https://pubmed.ncbi.nlm.nih.gov/22190040/)
[Wang X, et al, m6A in photoreceptor function and retinal degeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[Chen J, et al, Targeting m6A readers and writers in disease therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38735472/)